Enhanced TLR4 endothelial cell immunohistochemical expression in symptomatic carotid atherosclerotic plaques

Bibliography

• Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med 1999;340:115-26
   PubMed Web of Science ®Google Scholar
• Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:1876-90
   PubMed Web of Science ®Google Scholar
• Bobryshev YV. Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. Eur Heart J 2005;26:1700-4
   PubMed Web of Science ®Google Scholar
• Pasterkamp G, Van Keulen JK, De Kleijn DP. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest 2004;34:328-34
   PubMed Web of Science ®Google Scholar
• Tobias P, Curtiss LK. Thematic review series: the immune system and atherogenesis. Paying the price for pathogen protection: toll receptors in atherogenesis. J Lipid Res 2005;46:404-11
   PubMed Web of Science ®Google Scholar
• Curtiss LK, Tobias PS. The toll of Toll-like receptors, especially toll-like receptor 2, on murine atherosclerosis. Curr Drug Targets 2007;8:1230-8
   PubMed Web of Science ®Google Scholar
• Hommels MJ, Kroon AA, Netea MG, The Asp299Gly Toll-like receptor 4 polymorphism in advanced aortic atherosclerosis. Neth J Med 2007;65:203-7
   PubMed Web of Science ®Google Scholar
• Li H, Sun B. Toll-like receptor 4 in atherosclerosis. J Cell Mol Med 2007;11:88-95
   PubMed Web of Science ®Google Scholar
• Liu X, Ukai T, Yumoto H, Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis 2008;196:146-54
   PubMed Web of Science ®Google Scholar
• Katsargyris A, Klonaris C, Bastounis E, Theocharis S. Toll-like receptor modulation: a novel therapeutic strategy in cardiovascular disease? Expert Opin Ther Targets 2008;12:1329-46
   PubMed Web of Science ®Google Scholar
• Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002;105:1158-61
   PubMed Web of Science ®Google Scholar
• Xu XH, Shah PK, Faure E, Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001;104:3103-8
   PubMed Web of Science ®Google Scholar
• Liapis CD, Bell PR, Mikhailidis D, ESVS guidelines. Invasive treatment for carotid stenosis: indications, techniques. Eur J Vasc Endovasc Surg 2009;37:1-19
   PubMed Web of Science ®Google Scholar
• Howard G, Prineas R, Moy C, Racial and geographic differences in awareness, treatment, and control of hypertension: the REasons for Geographic And Racial Differences in Stroke study. Stroke 2006;37:1171-8
   PubMed Web of Science ®Google Scholar
• Virmani R, Kolodgie FD, Burke AP, Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20:1262-75
   PubMed Web of Science ®Google Scholar
• Arbour NC, Lorenz E, Schutte BC, TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25:187-91
   PubMed Web of Science ®Google Scholar
• Kiechl S, Lorenz E, Reindl M, Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002;347:185-92
   PubMed Web of Science ®Google Scholar
• Ameziane N, Beillat T, Verpillat P, Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003;23:e61-4
   PubMed Web of Science ®Google Scholar
• Vainas T, Stassen FR, Bruggeman CA, Synergistic effect of Toll-like receptor 4 and CD14 polymorphisms on the total atherosclerosis burden in patients with peripheral arterial disease. J Vasc Surg 2006;44:326-32
   PubMed Web of Science ®Google Scholar
• Michelsen KS, Wong MH, Shah PK, Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004;101:10679-84
   PubMed Web of Science ®Google Scholar
• Bjorkbacka H, Kunjathoor VV, Moore KJ, Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004;10:416-21
   PubMed Web of Science ®Google Scholar
• Shiraki R, Inoue N, Kobayashi S, Toll-like receptor 4 expressions on peripheral blood monocytes were enhanced in coronary artery disease even in patients with low C-reactive protein. Life Sci 2006;80:59-66
   PubMed Web of Science ®Google Scholar
• Methe H, Kim JO, Kofler S, Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005;111:2654-61
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999;138:S419-20
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391-7
   PubMed Web of Science ®Google Scholar
• Spagnoli LG, Mauriello A, Sangiorgi G, Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke. JAMA 2004;292:1845-52
   PubMed Web of Science ®Google Scholar
• Spagnoli LG, Bonanno E, Sangiorgi G, Mauriello A. Role of inflammation in atherosclerosis. J Nucl Med 2007;48:1800-15
   PubMed Web of Science ®Google Scholar
• Labrum R, Bevan S, Sitzer M, Toll receptor polymorphisms and carotid artery intima-media thickness. Stroke 2007;38:1179-84
   PubMed Web of Science ®Google Scholar
• Martin-Ventura JL, Blanco-Colio LM, Munoz-Garcia B, NF-κB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability. Stroke 2004;35:458-63
   PubMed Web of Science ®Google Scholar
• Wilson SH, Best PJ, Edwards WD, Nuclear factor-κB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. Atherosclerosis 2002;160:147-53
   PubMed Web of Science ®Google Scholar
• Tureyen K, Vemuganti R, Salamat MS, Dempsey RJ. Increased angiogenesis and angiogenic gene expression in carotid artery plaques from symptomatic stroke patients. Neurosurgery 2006;58:971-977; discussion 971-977
   PubMed Web of Science ®Google Scholar
• McCarthy MJ, Loftus IM, Thompson MM, Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J Vasc Surg 1999;30:261-8
   PubMed Web of Science ®Google Scholar
• Mofidi R, Crotty TB, McCarthy P, Association between plaque instability, angiogenesis and symptomatic carotid occlusive disease. Br J Surg 2001;88:945-50
   PubMed Web of Science ®Google Scholar
• Giannoni MF, Vicenzini E, Citone M, Contrast carotid ultrasound for the detection of unstable plaques with neoangiogenesis: a pilot study. Eur J Vasc Endovasc Surg 2009;37:722-7
   PubMed Web of Science ®Google Scholar
• Frantz S, Vincent KA, Feron O, Kelly RA. Innate immunity and angiogenesis. Circ Res 2005;96:15-26
   PubMed Web of Science ®Google Scholar
• Pollet I, Opina CJ, Zimmerman C, Bacterial lipopolysaccharide directly induces angiogenesis through TRAF6-mediated activation of NF-κB and c-Jun N-terminal kinase. Blood 2003;102:1740-2
   PubMed Web of Science ®Google Scholar
• Pinhal-Enfield G, Ramanathan M, Hasko G, An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A2A receptors. Am J Pathol 2003;163:711-21
   PubMed Web of Science ®Google Scholar
• Erickson B, Sperber K, Frishman WH. Toll-like receptors: new therapeutic targets for the treatment of atherosclerosis, acute coronary syndromes, and myocardial failure. Cardiol Rev 2008;16:273-9
   PubMed Web of Science ®Google Scholar
• Wang L, Li D, Yang K, Toll-like receptor-4 and mitogen-activated protein kinase signal system are involved in activation of dendritic cells in patients with acute coronary syndrome. Immunology 2008;125:122-30
   PubMed Web of Science ®Google Scholar
• Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109:III39-43
   PubMed Web of Science ®Google Scholar
• Martin-Ventura JL, Blanco-Colio LM, Gomez-Hernandez A, Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 2005;36:1796-800
   PubMed Web of Science ®Google Scholar
• Hollestelle SC, De Vries MR, Van Keulen JK, Toll-like receptor 4 is involved in outward arterial remodeling. Circulation 2004;109:393-8
   PubMed Web of Science ®Google Scholar
• Hamann L, Gomma A, Schroder NW, A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis. J Mol Med 2005;83:478-85
   PubMed Web of Science ®Google Scholar
• Redgrave JN, Lovett JK, Gallagher PJ, Rothwell PM. Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms: the Oxford plaque study. Circulation 2006;113:2320-8
   PubMed Web of Science ®Google Scholar
• Peeters W, Hellings WE, de Kleijn DP, Carotid atherosclerotic plaques stabilize after stroke: insights into the natural process of atherosclerotic plaque stabilization. Arterioscler Thromb Vasc Biol 2009;29:128-33
   PubMed Web of Science ®Google Scholar
• Carr S, Farb A, Pearce WH, Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. J Vasc Surg 1996;23:755-65; discussion 765-756
   PubMed Web of Science ®Google Scholar
• Mauriello A, Sangiorgi GM, Virmani R, A pathobiologic link between risk factors profile and morphological markers of carotid instability. Atherosclerosis 2009; published online 3 August 2009, doi:10.1016/j.atherosclerosis.2009.07.048
   Web of Science ®Google Scholar